James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

9 Best Stocks to Buy on U.S.-China Trade Optimism

Skyworks Solutions, Deer and Walmart are just three of the best stocks to own if and when the trade war finally ends.

3 Big Stock Charts for Monday: Caterpillar, Lamb Weston and CF Industries

The stock charts of CAT, CF and LW stock are getting the new trading week going at major tipping points. Here's what you need to know.

New Pressure on China Might Just Boost Applied Materials Stock

It's too soon to buy or sell Applied Materials stock based on the development, but it's a development AMAT shareholders will want to keep in mind.

Can 5G Really Boost Verizon Stock?

It's not yet a reason to buy or sell VZ stock, but Verizon does need to start offering clear reasons it's all-in on 5G.

Pfizer Stock Suffers From an Underappreciated Drugs Pipeline

PFE stock hasn't been a terribly rewarding name to own since the middle of last year, but Pfizer is doing everything it's supposed to do.